Hepatitis B e antigen-positive chronic hepatitis B: Natural history and treatment

Seminars in Liver Disease

Volumn 26, Issue 2, 2006, Pages 116-129

  Feld, Jordan J ^a   Heathcote, E Jenny ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Drug resistance; HBeAg seroconversion; Immunotolerant state; Nucleos(t)ide therapies; Pegylated interferon; Risk factors; Severe hepatitis B

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALCOHOL; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; ENTECAVIR; HEPATITIS B(E) ANTIGEN; HLA ANTIGEN; LAMIVUDINE; LIVER ENZYME; MONOCLONAL ANTIBODY; NUCLEOSIDE ANALOG; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; TENOFOVIR; VIRUS DNA;

AGING; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; CHRONIC HEPATITIS; CLINICAL PRACTICE; COMORBIDITY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG COST; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; DRUG TREATMENT FAILURE; ENVIRONMENTAL FACTOR; ETHNIC GROUP; GENOTYPE; HAPLOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; KIDNEY FUNCTION TEST; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER TOXICITY; NEPHROTOXICITY; NONHUMAN; OBESITY; PATHOGENESIS; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING TEST; SEROCONVERSION; SEX DIFFERENCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS HEPATITIS; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; DISEASE PROGRESSION; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; RISK FACTORS; TREATMENT OUTCOME;

EID: 33646358475     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-939750     Document Type: Review

References (82)

1. Prince AM. Relation of Australia SH antigens. Lancet 1968;2:462-463
2. Milich DR, Jones JE, Hughes JL, et al. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci USA 1990;87:6599-6603
3. Chen M, Sallberg M, Hughes J, et al. Immune tolerance split between hepatitis B virus precore and core proteins. J Virol 2005;79:3016-3027
4. Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004;53:1363-1365
5. Rawal BK, Parida S, Watkins RP, et al. Symptomatic reactivation of hepatitis B in pregnancy. Lancet 1991;337:364
6. Aroldi A, Lampertico P, Montagnino G, et al. Natural history of hepatitis B and C in renal allograft recipients. Transplantation 2005;79:1132-1136
7. Thursz MR, Kwiatkowski D, Allsopp CE, et al. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med 1995;332:1065-1069
8. Evans AA, O'Connell AP, Pugh JC, et al. Geographic variation in viral load among hepatitis B carriers with differing risks of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 1998;7:559-565
9. Wai C-T, Fontana RJ. Clinical significance of hepatitis B virus genotypes, variants, and mutants. Clin Liver Dis 2004; 8:321-352
10. Tanaka H, Tsukuma H, Yamano H, et al. Prospective study on the risk of hepatocellular carcinoma among hepatitis C virus-positive blood donors focusing on demographic factors, alanine aminotransferase level at donation and interaction with hepatitis B virus. Int J Cancer 2004;112: 1075-1080
11. Colin J-F, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999;29:1306-1310
12. Di Martino V, Thevenot T, Colin JF, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002; 123:1812-1822
13. Zanati SA, Locarnini SA, Dowling JP, et al. Hepatic failure due to fibrosing cholestatic hepatitis in a patient with presurface mutant hepatitis B virus and mixed connective tissue disease treated with prednisolone and chloroquine. J Clin Virol 2004;31:53-57
14. Donato F, Tagger A, Gelatti U, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002;155:323-331
15. Gu D, Reynolds K, Wu X, et al, Inter ASIA Collaborative Group. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 2005;365:1398-1405
16. Gordon A, McLean CA, Pedersen JS, et al. Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis. J Hepatol 2005;43:38-44
17. Bortolotti F, Cadrobbi P, Crivellaro C, et al. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterology 1990;99:805-810
18. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-1427
19. Lin S-M, Sheen I-S, Chien R-N, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999;29:971-975
20. Hsu Y-S, Chien R-N, Yeh C-T, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002;35:1522-1527
21. Chu C-M, Hung S-J, Lin J, et al. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004;116: 829-834
22. Marx G, Martin SR. Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins. J Infect Dis 2002;186:295-301
23. Lok ASF, Lai C-L. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children, Hepatology 1988;8:1130-1133
24. Evans AA, Fine M, London WT. Spontaneous seroconversion in hepatitis B e antigen-positive chronic hepatitis B: implication for interferon therapy. J Infect Dis 1997;176:845-850
25. Bell SJ, Lau A, Thompson A, et al. Chronic hepatitis B: recommendations for therapy based on the natural history of disease in Australian patients. J Clin Virol 2005;32:122-127
26. Liaw Y-F, Tai D-I, Chu C-M, et al. Acute exacerbation in chronic type B hepatitis: comparison between HBeAg and antibody-positive patients. Hepatology 1987;7:20-23
27. Lok ASF, Lai C-L. Acute exacerbations in Chinese Patients with chronic hepatitis B virus (HBV) infection. J Hepatol 1990;10:29-34
28. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001;120:1009-1022
29. Kao J-H, Chen P-J, Lai M-Y, et al. Acute exacerbations of chronic hepatitis B are rarely associated with superinfection of hepatitis B virus. Hepatology 2001;34:817-823
30. Yang H-I, Lu S-N, Liaw Y-F, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347: 168-174
31. Kao J-H, Chen P-J, Lai M-Y, et al. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000;118:554-559
32. Tsubota A, Arase Y, Ren F, et al. Genotype may correlate with liver carcinogenesis and tumor characteristics in cirrhotic patients infected with hepatitis B virus subtype adw. J Med Virol 2001;65:257-265
33. Chan HL-Y, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004;53:1494-1498
34. Chu C-J, Hussain M, Lok ASF. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002; 122-.1756-1762
35. Ito K, Tanaka Y, Orito E, et al. T1653 mutation in the box alpha increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B virus genotype C infection. Clin Infect Dis 2006;42:1-7
36. Sánchez-Tapias JM, Costa J, Mas A, et al. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002;123:1848-1856
37. Chu C-J, Keeffe EB, Han S-H, et al and the US HBV Epidemiology Study Group. Hepatitis B Virus genotypes in the United States: results of a nationwide study. Gastroenterology 2003;125:444-451
38. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004;2:87-106
39. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004;39:857-861
40. Perrillo RP, Lai CL, Liaw YF, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B, Hepatology 2002;36:186-194
41. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-2695
42. Yuen M-F, Yuan H-J, Wong DK-H, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005;54:1610-1614
43. Yao FY, Terrault NA, Freise C, et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001;34:411-416
44. van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004;39:804-810
45. Marcellin P, Asselah T, Boyer N. Treatment of chronic hepatitis B. J Viral Hepat 2005;12:333-345
46. Lau DT, Everhart J, Kleiner DE, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997;113:1660-1667
47. Song BC, Suh DJ, Lee HC, et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32:803-806
48. van Nunen AB, Hansen BE, Suh DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003;52:420-424
49. Chien RN, Yeh CT, Tsai SL, et al. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003;38:1267-1273
50. Lee CM, Ong GY, Lu SN, et al. Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J Hepatol 2002;37:669-674
51. Ryu SH, Chung YH, Choi MH, et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J Hepatol 2003; 39:614-619
52. Kagawa T, Watanabe N, Kanouda H, et al. Fatal liver failure due to reactivation of lamivudine-resistant HBV mutant. World J Gastroenterol 2004;10:1686-1687
53. Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005;142:240-250
54. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989;10:761-763
55. Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005; 54:1009-1013
56. Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002;36:1425-1430
57. Kao JH, Wu NH, Chen PJ, et al. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000;33:998-1002
58. Chow WC, Manns M, Paik SW, et al. Effect of ethnicity, genotype, gender, age and bodyweight on sustained response in a large, randomised study of peginterferon alfa-2a (40KD) (Pegasys) +/- lamivudine versus lamivudine alone for HBeAg-positive chronic hepatitis B. Hepatology 2005;42 (suppl 1):567A
59. Moskovitz DN, Osiowy C, Giles E, et al. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. J Viral Hepat 2005;12:398-404
60. Yuen MF, Wong DK, Sablon E, et al. Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. Antivir Ther 2003;8:531-534
61. Westland C, Delaney W, Yang H, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology 2003;125:107-116
62. ter Borg MJ, Flink HJ, Janssen HL, et al. Delayed viral decline is associated with highest sustained response rate during peginterfon treatment for HBeAg-positive chronic hepatitis B. Hepatology 2005;42(suppl 1):575A
63. Flink HJ, Sprengers D, Hansen BE, et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon α-2b therapy. Gut 2005;54:1604-1609
64. Nair S, Perrillo RP. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? Hepatology 2001;34:1021-1026
65. Fried MW, Liaw YF, Luo KX, et al. Role of baseline and on-treatment quantitative HBeAg in predicting response to peginterferon alfa-2a (40KD) (pegasys) monotherapy in a large, multinational trial of patients with chronic hepatitis B. Hepatology 2005;42(suppl 1):268A
66. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-129
67. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005;142:821-831
68. Stephan C, Berger A, Carlebach A, et al. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. J Antimicrob Chemother 2005;56:1087-1093
69. Bessesen M, Ives D, Condreay L, et al. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999;28:1032-1035
70. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531
71. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125:1742-1749
72. Liaw YF. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir Chem Chemother 2001;12(suppl 1):67-71
73. Nafa S, Ahmed S, Tavan D, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000;32:1078-1088
74. Liaw YF, Chien RN, Yeh CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30: 567-572
75. Lampertico P, Vigano M, Manenti E, et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005;42: 1414-1419
76. Wong VW, Chan HL, Wong ML, et al. Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants. Aliment Pharmacol Ther 2004; 19:323-329
77. Fung SK, Andreone P, Han SH, et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005;43:937-943
78. Osiowy C, Heathcote EJ, Zoulim F, et al. Resistance to adefovir dipivoxil in patiens with lamivudine-resistant chronic hepatitis B. Hepatology 2005;42(suppl 1):586A
79. Brunelle MN, Jacquard AC, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005;41:1391-1398
80. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-816
81. Sung JJY, Lai JY, Zeusem S, et al. A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B (CHB): week 52 analysis. J Hepatol 2003;38(suppl 2):69
82. Ghany M, Lutchman G, Kleiner D, et al. Lamvudine and adefovir versus adefovir alone for HBeAg-positive chronic hepatitis B. Hepatology 2005;42(suppl 1):591A